Current Issue : January-March Volume : 2024 Issue Number : 1 Articles : 5 Articles
The primary aim of this retrospective study was to investigate the potential effectiveness of autologous platelet gel as a method for facial volume restoration and skin rejuvenation. High-frequency ultrasonography was utilized to assess the outcomes of the treatment. The study included a cohort of ten female patients aged between 40 and 50 who actively participated in the research. They reported moderate-to-severe static and dynamic wrinkles, volume loss, thinning, and roughness of the skin. Each patient received one session of autologous platelet gel injections. The gel was prepared accordingly with the manufacturer’s (INNMEDIS, ATR™) instructions. Medium viscosity gel was injected into the superficial subdermal fat pads in the temples, as well as in the middle and lower face areas, to improve facial volume. A high-frequency ultrasound (US) device was employed to quantify skin density, skin thickness, and the depth of nasolabial folds. The US images were captured at three time points: before gel administration, one month after the procedure, and three months after the procedure. The imaging focused on the nasolabial folds area to monitor changes and assess the effectiveness of the treatment over time. Based on the analyses, the use of autologous platelet gel is beneficial towards improving skin density and decreasing nasolabial fold depth. However, further research should be conducted into the gel’s effects on dermis thickness to achieve a stronger, more statistically significant conclusion. The level of satisfaction of the enrolled patients regarding their facial appearance was evaluated using the visual analogue scale (VAS). The VAS assessment revealed an average score of 4.1 before the commencement of the treatment, an average score of 7.9 one month after the treatment, and an average score of 7.5 three months following the treatment. The results indicate a significant increase in patient satisfaction following treatment completion. Autologous platelet gel appears to hold promise as a treatment option for volume replacement and skin rejuvenation, making it an attractive choice for individuals seeking natural skin treatments. Despite the encouraging findings from this observation, further validation is required through a larger controlled study to definitively confirm whether autologous platelet gel is indeed an effective method for volume replacement and skin rejuvenation....
Background. Acne is a prevalent skin disorder that primarily affects seborrheic areas. It occurs due to hair follicle obstruction and subsequent inflammation. Patients with acne often exhibit compromised skin barrier function and sensitivity, making treatment challenging. Objectives. This study aimed to investigate the occurrence of acne complicated by sensitive skin and explore the associated physiological changes. Methods. The lactic acid test and capsaicin test were employed to identify subjects with simple acne and those with acne and sensitive skin. Physiological characteristics were assessed in both groups. Two random groups were selected from the subjects with acne and sensitive skin. One group received treatment for acne alone, while the other group received combined treatment for acne and sensitive skin care. The efficacy and physiological function of the two groups were compared after treatment. Results. Among 170 acne patients, 99 were identified as having acne with sensitive skin. Patients with acne and sensitive skin exhibited significantly higher scores on the lactic acid test and capsaicin test compared to those with simple acne. They also showed increased transepidermal water loss (TEWL), decreased skin cuticle hydration (SCH), thinner epidermis, and thicker blood vessels. The group receiving combined treatment demonstrated a more significant reduction in the number of skin lesions and IGA scores compared to the group receiving treatment for acne alone. They also exhibited lower scores on the lactate and capsaicin tests, along with decreases in TEWL and increases in SCH. Conclusions. Acne with sensitive skin is highly prevalent and is associated with distinct physiological characteristics. Combined treatment targeting both acne and sensitive skin yields excellent clinical outcomes and improves skin’s physiological function. These findings underscore the importance of considering sensitive skin in the clinical management of acne....
Objectives. To determine the efficacy of platelet-rich plasma in treating alopecia areata. Methods. A systematic search was carried out in PubMed, Embase, and the Cochrane Library databases to identify any article evaluating the efficacy of platelet-rich plasma for the treatment of alopecia areata and comparing platelet-rich plasma with other treatment modalities. Results. Nine studies were included based on our inclusion criteria with a total of 616 patients. Various evaluations of alopecia areata treatment efficacy with platelet-rich plasma, including the comparison between platelet-rich plasma and triamcinolone acetonide, minoxidil, placebo, and other methods, such as fractional carbon dioxide laser and microneedling, were conducted in the included studies. The main results revealed that platelet-rich plasma and triamcinolone acetonide are both effective in the treatment of alopecia areata. However, the treatment response was in favor of platelet-rich plasma. Also, minoxidil showed positive effects on the treatment of alopecia areata alongside platelet-rich plasma. Platelet-rich plasma also has significantly better effects on alopecia areata compared to placebo. Most of the side effects of treatment of alopecia areata with platelet-rich plasma were minor, including burning sensation, pain during injection, erythema, edema, ecchymosis, crust formation, and headache. Conclusion. Based on the evidence reviewed, it is suggested that platelet-rich plasma is a safe and effective treatment option for alopecia areata. Furthermore, platelet-rich plasma has the advantage of being a steroid-sparing therapy, reducing the reliance on corticosteroids. The use of platelet-rich plasma is associated with fewer complications compared to other treatment modalities....
(1) Background: Endocrine Mucin-Producing Sweat Gland Carcinoma (EMPSGC) is a rare, low-grade, neuroendocrine-differentiated, cutaneous adnexal tumor, officially recognized by theWorld Health Organization (WHO) Skin Tumors Classification in 2018 as a separate entity and homologue of endocrine ductal carcinoma in situ (eDCIS)/solid papillary carcinoma of the breast. Although it is more frequent in the female sex, between 60 and 70 years old, in the peri-orbital region, EMPSGC has also been described in the male sex, in subjects under 60 and over 80, and in extraeyelid localizations (cheek, temple, scalp), but also in extra-facial localizations (chest and scrotum). (2) Methods: We present the clinical case of a 71-year-old woman with an undated lesion of the scalp, which presented as a nodule, skin-colored, and 2.5 cm in maximum diameter. We also conduct a comprehensive literature review from 1997 to the end of 2022, consulting PubMed, Scopus, Web of Science (WoS), and Google Scholar using the following keywords: “Endocrine mucin-producing sweat gland carcinoma” and/or “EMPSGC” and/or “skin” and “cutaneous neoplasms”. In addition, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 253 patients were recorded; 146 were females (57.7%) and 107 were males (42.2%). The vast majority of the lesions were in the eyelids (peri-ocular region), and only a minority of cases involved the cheeks, supra-auricular, retro-auricular, and occipital region, with very rare cases in the scalp, to which the present is also added. (4) Conclusions: The morphological and immunophenotypical features are essential both for the correct diagnosis and to be able to classify this lesion among the corresponding eDCIS/solid papillary carcinoma of the breast, with neuroendocrine differentiation. Recent papers have attempted to shed light on the molecular features of EMPSGC, and much remains to be conducted in the attempt to subtype the molecular profiles of these entities. Future studies with large case series, and especially with molecular biology techniques, will be needed to further add information about EMPSGC and its relationship in the PCMC spectrum....
Background Axial spondyloarthritis (axSpA) is known to be associated with several extra-skeletal manifestations (ESM), including the inflammatory skin disease psoriasis. It is important to recognize and diagnose psoriasis timely in axSpA in order to provide optimal treatment and outcome for both axSpA and psoriasis. Methods In this observational study, all patients from the Dutch Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort included before June 2016 were sent a questionnaire with self-screening psoriasis questions including prototypical color pictures. Results Of the 592 questionnaires sent, 448 (75.7%) were eligible for analysis. Of these 448 respondents, 58 (13%) had a positive self-screening for psoriasis symptoms, currently or in the past. In 28 (48%) of 58 patients, psoriasis diagnosis could be verified by medical records, resulting in a psoriasis prevalence rate of 6.3%. In comparison with patients with a confirmed psoriasis diagnosis, patients reporting psoriasis symptoms without a verified diagnosis mentioned more mild than moderate-severe psoriasis symptoms (25% vs. 3%, p = 0.02), and their psoriasis lesions were less often located on the torso area (3% vs. 18%, p = 0.04), the intergluteal cleft (0% vs. 25%, p = 0.02), and legs (7% vs. 43%, p < 0.01). Of the 31 axSpA patients who reported currently active psoriasis, 74% had only mild psoriasis symptoms. Conclusions Especially mild psoriasis seems often underdiagnosed in patients with axSpA using a patient questionnaire with prototypical pictures of psoriasis lesions. This questionnaire could be beneficial in tracing patients with undiagnosed psoriasis in daily clinical practice. As a next step, further validation of this questionnaire is needed....
Loading....